vinzolidine and Hodgkin-Disease

vinzolidine has been researched along with Hodgkin-Disease* in 1 studies

Other Studies

1 other study(ies) available for vinzolidine and Hodgkin-Disease

Article	Year
Phase II trial of vinzolidine, an oral vinca alkaloid, in Hodgkin's disease and non-Hodgkin's lymphoma. Cancer treatment reports, 1984, Volume: 68, Issue:11 Vinzolidine, a semisynthetic vinblastine derivative, was tested in an oral formulation in 21 heavily pretreated patients with lymphoma. Partial remissions were seen in four patients with Hodgkin's disease (50%) and in one patient with non-Hodgkin's lymphoma (8%). Significant side effects included neurotoxicity and dose-related myelosuppression. Vinzolidine is an active vinca alkaloid which merits further evaluation in patients with lymphoma, particularly Hodgkin's disease. Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Hodgkin Disease; Humans; Lymphoma; Male; Middle Aged; Vinca Alkaloids	1984

Article

Year

Phase II trial of vinzolidine, an oral vinca alkaloid, in Hodgkin's disease and non-Hodgkin's lymphoma.

Cancer treatment reports, 1984, Volume: 68, Issue:11

Vinzolidine, a semisynthetic vinblastine derivative, was tested in an oral formulation in 21 heavily pretreated patients with lymphoma. Partial remissions were seen in four patients with Hodgkin's disease (50%) and in one patient with non-Hodgkin's lymphoma (8%). Significant side effects included neurotoxicity and dose-related myelosuppression. Vinzolidine is an active vinca alkaloid which merits further evaluation in patients with lymphoma, particularly Hodgkin's disease.

Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Hodgkin Disease; Humans; Lymphoma; Male; Middle Aged; Vinca Alkaloids

1984